GLG News by Aloxi Prescribers for CINV (US)

Michael GrossbardProfessor of Clinical MedicineCOLUMBIA UNIVERSITY, COLLEGE OF PHYSICIANS & SURGEONS What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Avastin Raises Risk of Clots: New News?

December 1, 2008

Scientists recommend 'black box' for Avastin | www.fiercepharma.com

In pooled data from 8000 patients across 15 studies, the risk of blood clots was increased by 12% in patients receiving Avastin.

Michael GrossbardProfessor of Clinical MedicineCOLUMBIA UNIVERSITY, COLLEGE OF PHYSICIANS & SURGEONS What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Amgen Rewords Label: Less Use of Procrit

August 29, 2008

Amgen Told to Reword Drug Label | www.nytimes.com

The FDA required Amgen to revise the label for Procrit and Aranesp so that these agents are not used until a patient's hemoglobin drops below 10 or in the setting of potentially curative therapy.

Michael GrossbardProfessor of Clinical MedicineCOLUMBIA UNIVERSITY, COLLEGE OF PHYSICIANS & SURGEONS What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Transparency in Healthcare: How to Assess?

August 29, 2008

Transparency in Healthcare | www.hospitalimpact.org

The author argues that transparency in healthcare will be an important step forward for the consumer.

Michael GrossbardProfessor of Clinical MedicineCOLUMBIA UNIVERSITY, COLLEGE OF PHYSICIANS & SURGEONS What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Avastin: Worth the Cost?

August 29, 2008

Costly Cancer Drug Offers Hope, but Also a Dilemma | www.nytimes.com

Avastin improves survival in colon cancer and lung cancer and improves progression free survival in breast cancer- clinically meaningful outcomes.  Yet these gains are of relatively short duration and the cost of Avastin is significant- 50,000 to 100,000 dollars per year.

Michael GrossbardProfessor of Clinical MedicineCOLUMBIA UNIVERSITY, COLLEGE OF PHYSICIANS & SURGEONS What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

NICE States Novel Therapies for Renal Cell Cancer Too Costly

August 28, 2008

UK Says Kidney Cancer Drugs Are Too Pricey | www.pharmalot.com

NICE has stated that the cost of several novel agents for the treatment of renal cell cancer including Sutent, Torisel, Avastin, and Nexavar exceeds the benefit when assessed by quality adjusted life years (QALY) gained from the therapies.

Michael GrossbardProfessor of Clinical MedicineCOLUMBIA UNIVERSITY, COLLEGE OF PHYSICIANS & SURGEONS What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

One Drug Many Uses: Prove It

July 7, 2008

One drug, many uses. Good idea? | www.indystar.com

Lilly has devoted substantial energy/expense in developing Cymbalta for many indications.  Is this at the expense of developing novel agents? 

Michael GrossbardProfessor of Clinical MedicineCOLUMBIA UNIVERSITY, COLLEGE OF PHYSICIANS & SURGEONS What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Can China Make Generics Better than They Make Toys

July 7, 2008

China Muscles In On The Generics Industry | www.pharmalot.com

Several Chinese companies are set to enter the generic drug market ove the next year.  If these agents are demonstrated to be safe, they could have a large impact on the generic drug industry.

Michael GrossbardProfessor of Clinical MedicineCOLUMBIA UNIVERSITY, COLLEGE OF PHYSICIANS & SURGEONS What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Avastin Effecitve in Lung and Breast Cancer But is it Cost Effective?

July 7, 2008

Roche decision denies cancer drug to Britons | www.ft.com

Roche has elected not to provide information on the cost effectiveness and clinical effectiveness of Avastin in breast cancer to the medicine advisory board of the British government.  As such, the drug will not be able for first line treatment of these diseases in Britain.

Michael GrossbardProfessor of Clinical MedicineCOLUMBIA UNIVERSITY, COLLEGE OF PHYSICIANS & SURGEONS What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

New Agents Needed for Therapy of Neuropathy in Cancer Patients- Is AL-309 the Agent?

May 19, 2008

Allon data demonstrate potential of AL-309 as a new neuropathy treatment | www.pipelinereview.com

Cancer patients frequently develop neuropathy as a results of chemotherapy agents including oxaliplatin, paclitaxel, vinca alkaloids, and Velcade.  Because many such patients have extended survival or receive treatment with curative intent, the resultant neuropathy can limit quality of life significantly.  New agents are much needed for the prevention and treatment of neuropathy.   

Michael GrossbardProfessor of Clinical MedicineCOLUMBIA UNIVERSITY, COLLEGE OF PHYSICIANS & SURGEONS What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Proteosome Inhibition with Carfilzomib is Promising Therapeutic Avenue

May 19, 2008

Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients with Relapsed Solid Tumors | www.pipelinereview.com

Carfilzomib is a nvelo prteosome inhibitor.  Bortezomib, the only proteosome inhibitor that is currently FDA approve, has shown significant activity in myeloma and mantle cell NHL and is being tested in other hematologic malignancies.  If Carfilzomib has improved toxicty and greater efficacy than Bortezomib, it may have a significant role in cancer therapy.

Page : 12345678910Next1 to 10 of 95

Leading institutions connect with members of the Healthcare councils through GLG

Most Popular Healthcare News